Ken Griffin An2 Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in An2 Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 1,556,554 shares of ANTX stock, worth $3.53 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,556,554
Previous 1,556,842
0.02%
Holding current value
$3.53 Million
Previous $31.9 Million
84.14%
% of portfolio
0.0%
Previous 0.01%
Shares
6 transactions
Others Institutions Holding ANTX
# of Institutions
55Shares Held
13.2MCall Options Held
0Put Options Held
0-
Tcg Crossover Management, LLC Palo Alto, CA1.56MShares$3.53 Million0.53% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA1.39MShares$3.15 Million0.24% of portfolio
-
Bvf Inc San Francisco, CA1.24MShares$2.81 Million0.12% of portfolio
-
Janus Henderson Group PLC London, X01.22MShares$2.77 Million0.0% of portfolio
-
Avidity Partners Management LP Dallas, TX1.15MShares$2.61 Million0.14% of portfolio
About AN2 Therapeutics, Inc.
- Ticker ANTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 19,402,700
- Market Cap $44M
- Description
- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...